Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
NANJING, China, April 18, 2022 /PRNewswire/ — On April 15, 2022, Simcere Pharmaceutical (2096.HK), an innovation and R&D driven pharmaceutical company in China [...]